DuPont is paying Merck $2.6 billion to buy out 50% stake in drug venture
Article Abstract:
Dupont Co. has announced that it will pay $2.6 billion for Merck & Co.Es portion of Dupont Merck Pharmaceutical Co. Kurt Landgraf, DupontEs executive vice president overseeing life sciences, stated that the pharmaceuticals unit would be a decisive factor in DupontEs life scienceEs rising about 35% of sales in 2002. Merck decided to divest itself of the unit, which made about $1.3 billion in sales in 1997, because Dupont wanted to build the business more quickly than did Merck. Mr. Landgraf stated that Dupont would take a one-time charge of about $1 billion because of the purchase.
Comment:
Dupont plans to pay $2.6 bil for Merck & Co.Es portion of Dupont Merck Pharmaceutical Co.
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
DuPont sees a lower profit for 2nd period
Article Abstract:
The CEO of DuPont Co., Charles Holliday, announced that the company's 1998 second-quarter earnings will fall by up to 15% compared to the same period in 1997. Mr. Holliday called DuPont's performance "totally unacceptable." The earnings will be far less that what experts on Wall Street expected. DuPont attributed the poor earnings to several problems such as bad weather that led to low agricultural chemical sales.
Comment:
Company's 1998 second-quarter earnings will fall by up to 15% compared to the same period in 1997
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
BetzDearborn stock soars while shares of Hercules drop
Article Abstract:
Hercules Inc.'s deal to pay a premium of 100% to acquire BetzDearborn Inc. led to a rise in BetzDearborn shares. However, the deal led to a drop in Hercules' stock. Many saw Hercules' acquisition of BetzDearborn, a specialty-chemicals firm, as a major strategical victory. However, the purchase price of $72 per share, together with Hercules' assumption of $700 million in debt, hurt the company's share value.
Comment:
Hercules purchase of BetzDearborn increases BetzDearborn's share value but hurts Hercules' stock
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Qwest is acquiring LCI for $4.43 billion, creating No. 4 long-distance provider. BellSouth pushes harder in Latin America
- Abstracts: Nabisco to take $406 million charge, cut 6% of work force in retrenchment. Vlasic hopes new marketing plan will perk up sales
- Abstracts: British Air's new no-frills carrier, Go, to battle its discount rivals. AMR-British air linkup just keeps circling, circling
- Abstracts: DuPont puts stock in global security force. DuPont Merck sued over licensing deal. DuPont buys out Merck
- Abstracts: CBS affiliates to share costs for first time. High-stakes battle for momentum. Can football revive CBS?